Nice to see an anticipated $900k in Q2FY19 from R&D grants - couple that with the PromarkerD sales and we wont be seeing sub-30c with those revenue figures.
China commercialization deal has gone a bit quiet but I do recall Richard mentioning they were facing challenges with getting into the China market. I hope to see more news on this in the Annual Report. Its definitely something to look forward to.
When it happens - its going be a firework display
BEIJING, 6 April 2016 - Almost 10% of all adults in China – about 110 million people – currently live with diabetes. Without urgent action to reduce lifestyle risk factors like unhealthy diet and lack of physical activity, that number is expected to increase to 150 million by 2040 – with major health, social and economic consequences. http://www.wpro.who.int/china/mediacentre/releases/2016/20160406/en/
A measly $1 dollar in royalty from China alone would make us very comfortable! Imagine a 10% PromarkerD penetration rate in China with over 110M diabetics. A dream for now but the potential is there!
$2.5M on hand gives us enough cash to last another 12months, who knows what new medical breakthroughs the Promarker platform will achieve in that time frame.
Busselton Health Lung Disease research results 'should' be out in the next ~3months or so.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)